These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30394899)

  • 21. Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes.
    Stieger N; Worthmann K; Teng B; Engeli S; Das AM; Haller H; Schiffer M
    Metabolism; 2012 Aug; 61(8):1073-86. PubMed ID: 22365040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse.
    Landau D; Segev Y; Afargan M; Silbergeld A; Katchko L; Podshyvalov A; Phillip M
    Kidney Int; 2001 Aug; 60(2):505-12. PubMed ID: 11473633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Podocytes, glucose and insulin.
    Welsh GI; Coward RJ
    Curr Opin Nephrol Hypertens; 2010 Jul; 19(4):379-84. PubMed ID: 20539231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
    Wang S; Li Y; Zhao J; Zhang J; Huang Y
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
    Wang A; Ziyadeh FN; Lee EY; Pyagay PE; Sung SH; Sheardown SA; Laping NJ; Chen S
    Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1657-65. PubMed ID: 17804483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Podocyte hypertrophy in diabetic nephropathy.
    Kim NH
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S14-6. PubMed ID: 16174280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes.
    Segev Y; Eshet R; Yakir O; Haim N; Phillip M; Landau D
    Diabetologia; 2007 Jun; 50(6):1327-34. PubMed ID: 17443310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy?
    Reddy GR; Kotlyarevska K; Ransom RF; Menon RK
    Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):32-6. PubMed ID: 18090667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Podocyte derived TNF-α mediates monocyte differentiation and contributes to glomerular injury.
    Nishad R; Mukhi D; Kethavath S; Raviraj S; Paturi ASV; Motrapu M; Kurukuti S; Pasupulati AK
    FASEB J; 2022 Dec; 36(12):e22622. PubMed ID: 36421039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal bone morphogenetic protein-7 protects against diabetic nephropathy.
    Wang S; de Caestecker M; Kopp J; Mitu G; Lapage J; Hirschberg R
    J Am Soc Nephrol; 2006 Sep; 17(9):2504-12. PubMed ID: 16899516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
    Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
    Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy.
    Wolf G; Chen S; Ziyadeh FN
    Diabetes; 2005 Jun; 54(6):1626-34. PubMed ID: 15919782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of growth hormone hypersecretion on the adult human kidney.
    Grunenwald S; Tack I; Chauveau D; Bennet A; Caron P
    Ann Endocrinol (Paris); 2011 Dec; 72(6):485-95. PubMed ID: 22098791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Role of podocyte damage in the pathogenesis of glomerulosclerosis and tubulointerstitial lesions: findings in the growth hormone transgenic mouse model of progressive nephropathy].
    Wanke R; Wolf E; Brem G; Hermanns W
    Verh Dtsch Ges Pathol; 2001; 85():250-6. PubMed ID: 11894406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
    Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
    Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth Hormone and IGF1 Actions in Kidney Development and Function.
    Gurevich E; Segev Y; Landau D
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperfiltration and diabetic nephropathy: is it the beginning? Or is it the end?
    Castellino P; Shohat J; DeFronzo RA
    Semin Nephrol; 1990 May; 10(3):228-41. PubMed ID: 2190280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of growth hormone on the development of diabetic kidney disease in rats.
    Landau D; Israel E; Rivkis I; Kachko L; Schrijvers BF; Flyvbjerg A; Phillip M; Segev Y
    Nephrol Dial Transplant; 2003 Apr; 18(4):694-702. PubMed ID: 12637637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The renal endothelium in diabetic nephropathy.
    Eleftheriadis T; Antoniadi G; Pissas G; Liakopoulos V; Stefanidis I
    Ren Fail; 2013; 35(4):592-9. PubMed ID: 23472883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update.
    Ying Q; Wu G
    Ren Fail; 2017 Nov; 39(1):474-483. PubMed ID: 28413908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.